Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
biologic medication |
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
gptkb:L03AB13
|
| gptkbp:brand |
gptkb:Plegridy
|
| gptkbp:CASNumber |
1214988-34-7
|
| gptkbp:chemicalClass |
gptkb:insulin
|
| gptkbp:developer |
gptkb:Biogen
|
| gptkbp:form |
solution for injection
|
| gptkbp:frequency |
every 2 weeks
|
| gptkbp:halfLife |
about 78 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
peginterferon beta-1a
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:pegylated |
true
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
fever
headache muscle pain injection site reactions flu-like symptoms |
| gptkbp:status |
FDA approved
EMA approved |
| gptkbp:UNII |
6J9B8T8V8I
|
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:Plegridy
|
| gptkbp:bfsLayer |
6
|